These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2881941)

  • 1. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population.
    Morgenstern H; Glazer WM; Gibowski LD; Holmberg S
    J Chronic Dis; 1987; 40(4):319-27. PubMed ID: 2881941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Handedness and the risk of tardive dyskinesia.
    Morgenstern H; Glazer WM; Doucette JT
    Biol Psychiatry; 1996 Jul; 40(1):35-42. PubMed ID: 8780853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables.
    Mukherjee S; Rosen AM; Cardenas C; Varia V; Olarte S
    Arch Gen Psychiatry; 1982 Apr; 39(4):466-9. PubMed ID: 6121547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.
    Jeste DV; Lacro JP; Palmer B; Rockwell E; Harris MJ; Caligiuri MP
    Am J Psychiatry; 1999 Feb; 156(2):309-11. PubMed ID: 9989570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia in an outpatient population: prevalence and predisposing factors.
    Yassa R; Ananth J; Cordozo S; Ally J
    Can J Psychiatry; 1983 Aug; 28(5):391-4. PubMed ID: 6138143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia in northern Israel: preliminary study.
    Schwartz M; Silver H; Tal I; Sharf B
    Eur Neurol; 1993; 33(3):264-6. PubMed ID: 8096816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of tardive dyskinesia in a clinic population.
    Fleischhauer J; Kocher R; Hobi V; Gilsdorf U
    Psychopharmacology Suppl; 1985; 2():162-72. PubMed ID: 2860658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and epidemiologic aspects of tardive dyskinesia.
    Baldessarini RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):8-13. PubMed ID: 2858483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia: prevalence, incidence, and risk factors.
    Kane JM; Woerner M; Lieberman J
    Psychopharmacology Suppl; 1985; 2():72-8. PubMed ID: 2860662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors.
    Gureje O
    Psychol Med; 1989 Feb; 19(1):121-8. PubMed ID: 2567019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia?
    McDermid SA; Hood J; Bockus S; D'Alessandro E
    Can J Psychiatry; 1998 Aug; 43(6):629-31. PubMed ID: 9729692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent tardive dyskinesia: demographic and pharmacological risk factors.
    Muscettola G; Pampallona S; Barbato G; Casiello M; Bollini P
    Acta Psychiatr Scand; 1993 Jan; 87(1):29-36. PubMed ID: 8093821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.